In contrast to the agonist mAbs, antagonist anti-CD40 mAbs block the CD40/CD40LG pathway to inhibit the proliferation of malignant B cells, which highly express CD40, such as in CLL and NHL. Here, CD40 is linked to non-Hodgkin lymphoma.